Cover Image

In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia

The prognosis of patients with advanced-phase chronic myeloid leukemia (CML) remains dismal despite the availability of targeted therapies and allogeneic stem cell transplantation (allo-SCT). Increasing the antileukemic efficacy of the pretransplant conditioning regimen may be a strategy to increase...

Full description

Saved in:
Bibliographic Details
Main Authors: Radujković, Aleksandar (Author) , Luft, Thomas (Author) , Dreger, Peter (Author) , Ho, Anthony Dick (Author) , Jens Zeller, W. (Author) , Fruehauf, Stefan (Author) , Topaly, Julian (Author)
Format: Article (Journal) Editorial
Language:English
Published: 20 July 2014
In: Cancer chemotherapy and pharmacology
Year: 2014, Volume: 74, Issue: 2, Pages: 427-432
ISSN:1432-0843
DOI:10.1007/s00280-014-2533-6
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00280-014-2533-6
Verlag, lizenzpflichtig, Volltext: https://link.springer.com/article/10.1007%2Fs00280-014-2533-6
Get full text
Author Notes:Aleksandar Radujkovic · Thomas Luft · Peter Dreger · Anthony D. Ho · W. Jens Zeller · Stefan Fruehauf · Julian Topaly
Description
Summary:The prognosis of patients with advanced-phase chronic myeloid leukemia (CML) remains dismal despite the availability of targeted therapies and allogeneic stem cell transplantation (allo-SCT). Increasing the antileukemic efficacy of the pretransplant conditioning regimen may be a strategy to increase remission rates and duration. We therefore investigated the antiproliferative effects of nilotinib in combination with drugs that are usually used for conditioning: the alkylating agents mafosfamide, treosulfan, and busulfan.
Item Description:Gesehen am 04.09.2020
Physical Description:Online Resource
ISSN:1432-0843
DOI:10.1007/s00280-014-2533-6

Similar Items